Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
- Views Icon Views
- Share Icon Share
Simon Heller, João Filipe Raposo, Santiago Tofé, Wasim Hanif, Zbynek Schroner, Su Down, Thomas Blevins; Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes. Clin Diabetes 2022; cd220016. https://doi.org/10.2337/cd22-0016
Download citation file: